TARA
Protara Therapeutics Inc

5,528
Mkt Cap
$284.48M
Volume
997.00
52W High
$7.82
52W Low
$2.77
PE Ratio
-3.94
TARA Fundamentals
Price
$5.42
Prev Close
$5.26
Open
$5.32
50D MA
$6.08
Beta
1.21
Avg. Volume
1.21M
EPS (Annual)
-$1.34
P/B
1.44
Rev/Employee
$0.00
$76.12
Loading...
Loading...
News
all
press releases
Protara Therapeutics, Inc. (NASDAQ:TARA) Short Interest Up 48.0% in February
Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) saw a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 4,895,488 shares, an...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
FY2030 Earnings Forecast for TARA Issued By HC Wainwright
Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Protara Therapeutics in a research note issued...
MarketBeat·5d ago
News Placeholder
Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm...
MarketBeat·10d ago
News Placeholder
Protara Therapeutics (NASDAQ:TARA) Now Covered by JPMorgan Chase & Co.
JPMorgan Chase & Co. started coverage on shares of Protara Therapeutics in a report on Wednesday. They issued an "overweight" rating and a $27.00 target price for the company...
MarketBeat·13d ago
News Placeholder
Protara Therapeutics Highlights TARA-002 NMIBC Data, FDA Plans for Lymphatic Malformations at Oppenheimer Conf
Protara Therapeutics (NASDAQ:TARA) executives outlined progress across the company's two clinical-stage programs during a fireside chat at Oppenheimer's 36th Annual Healthcare Life Sciences...
MarketBeat·15d ago
News Placeholder
Protara Therapeutics (TARA) to Release Earnings on Wednesday
Protara Therapeutics (NASDAQ:TARA) will be releasing its Q4 2025 earnings before the market opens on Wednesday, March 4. (View Earnings Report at...
MarketBeat·20d ago
News Placeholder
Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU
Protara Therapeutics (NASDAQ:TARA) shared updated interim data from its ongoing Phase 2, open-label ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive...
MarketBeat·20d ago
News Placeholder
Does TARA Stock’s 15% After-Hours Slump Signal A Bargain After New Bladder Cancer Data?
The company is on track to initiate the Advanced-3 registrational trial in patients who have not previously received BCG in the second half of 2026.
Stocktwits·21d ago
News Placeholder
Protara Therapeutics (NASDAQ:TARA) Trading Up 2.3% - Should You Buy?
Protara Therapeutics (NASDAQ:TARA) Trading Up 2.3% - Should You Buy...
MarketBeat·1mo ago
News Placeholder
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of "Moderate Buy" from Analysts
Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the company, MarketBeat Ratings reports...
MarketBeat·2mo ago
<
1
2
...
>

Latest TARA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.